bioRxiv Science⌕ Search

Biology subjects

Menale, C.

Publications and source records attributed to Menale, C..

2 recordsLinked to original sources
bioRxiv2026

Primary Hyperparathyroidism Reveals Limited Adipose Remodeling in Human

BackgroundPreclinical models implicate the parathyroid hormone/parathyroid-hormone-related protein (PTH/PTHrP)-PTH1 receptor (PTH1R) axis in adipocyte lipolysis, adipose browning, and energy wasting. Whether this catabolic program is reproduced in vivo in humans remains unresolved. Primary hyperparathyroidism (PHPT), a condition of chronic endogenous PTH excess, provides a clinically relevant model to test the translational relevance of this pathway. MethodsWe combined population-scale analyses with a prospective human intervention study. PTH/PTH1R associations with body composition were evaluated in the UK Biobank and compared with PTH dynamics in cancer-associated cachexia using TRACERx proteomic data. In parallel, patients with PHPT were assessed before and after parathyroidectomy and compared with matched surgical controls. Biochemical parameters, circulating adipocytokines, DXA- and BIA-derived body composition, histology, UCP1 immunohistochemistry, and supraclavicular adipose tissue transcriptomic and proteomic profiles were integrated, with external validation in an independent supraclavicular adipose dataset. ResultsIn the UK Biobank, apparent positive associations between circulating PTH/PTH1R signals and fat or lean mass were markedly attenuated after matching for age, sex, and BMI, arguing against a disease-specific adiposity effect of PHPT. In TRACERx, circulating PTH did not increase across BMI-adjusted weight-loss grades. In the prospective cohort, parathyroidectomy normalized PTH, calcium, and phosphate but did not induce coherent changes in glucose metabolism, lipid profile, inflammatory markers, body weight, fat mass, lean mass, or thermogenic adipose signatures. Supraclavicular adipose histology, UCP1 staining, RNA-seq, proteomics, pathway analysis, and external dataset reanalysis converged on the absence of browning or thermogenic activation. By contrast, PHPT was associated with a selective adipose-related secretory phenotype: adiponectin, adipsin, and retinol-binding protein 4 were reversible after surgery, whereas lipocalin- 2 and thrombospondin-1 remained elevated. ConclusionsChronic endogenous PTH excess is not sufficient to induce a detectable thermogenic or energy- dissipating adipose program in humans under basal clinical conditions. These findings challenge direct extrapolation from rodent PTH/PTHrP models and reposition the human PTH-adipose axis as a selective secretory and remodeling pathway rather than a dominant driver of adipose browning or wasting. HighlightsO_LIPHPT provides an in vivo human model of chronic endogenous PTH excess. C_LIO_LIPTH/PTH1R associations with body composition are lost after stringent confounder control. C_LIO_LIParathyroidectomy normalizes mineral metabolism without inducing adipose browning or wasting. C_LIO_LISupraclavicular adipose histology, UCP1 staining, transcriptomics, and proteomics show no thermogenic activation. C_LIO_LIPHPT unmasks a selective adipose-related secretory signature with reversible and persistent components. C_LI

physiology↗
bioRxiv2026

Motor Neuron Dysfunction in SORD Deficiency: Implications for Therapeutic Development in Peripheral Neuropathies

Biallelic mutations in the sorbitol dehydrogenase (SORD) gene have been identified as one of the most common causes of autosomal-recessive Charcot-Marie-Tooth disease type 2 (CMT2) and distal hereditary neuropathy, collectively referred to as SORD deficiency. These mutations result in loss of sorbitol dehydrogenase activity, a key enzyme in the polyol pathway that metabolizes glucose, leading to marked accumulation of sorbitol in patient-derived fibroblasts. However, the mechanisms by which SORD dysfunction drives axonal degeneration remain poorly understood, and robust in vitro models of human SORD-deficient motor neurons (MNs) are still lacking. To address this gap, we established a human in vitro model of SORD deficiency by generating induced pluripotent stem cells (iPSCs) from fibroblasts affected individual carrying biallelic SORD mutations (SORDc.757delG/c.316_425+165del), and unaffected heterozygous carriers (SORDc.757delG/wt and SORDwt/c.316_425+165del). These iPSCs were subsequently differentiated into motor neuron progenitors (MNPs) and MNs. Comprehensive analysis of SORD-deficient human cells--including fibroblasts, MNPs, and MNs--revealed pronounced structural and functional abnormalities in the mitochondrial compartment, characterized by mitochondrial fragmentation and increased proton leak. Importantly, fibroblasts derived from two additional unrelated patients carrying the SORD mutation (SORDc.757delG/ c.757delG) further confirmed that SORD deficiency is associated with a mitochondrial phenotype. At the molecular level, SORD deficiency led to upregulation of aldose reductase (AR), another key enzyme of the polyol pathway, resulting in disruption of cellular redox homeostasis and increased oxidative stress. Consistent with these alterations, MNs derived from CMT2/SORD patients exhibited clear neurodegenerative features, including severe defects in neurite branching and synaptic architecture, ultimately impairing neuronal connectivity. Notably, pharmacological inhibition of AR effectively rescued both mitochondrial dysfunction and neuronal structural defects, supporting the targeting of AR as a promising therapeutic strategy for polyol pathway-associated neuropathies as CMT2/SORD and diabetic neuropathy.

cell biology↗